Helix BioPharma Corp. (HBP.TO)

1.2400 +0.2400 (+24.00%) At close: 03:38PM EDT

Helix BioPharma Corp.

401 Bay Street
Suite 2704 PO Box 4
Toronto, ON M5H 2Y4
Canada
905-841-2300
https://www.helixbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jacek Antas	Chairman & CEO	100.61k	N/A	N/A
Mr. Praveen Kumar Varshney F.C.A., FCA, FCPA, LLB	CFO & Corporate Secretary	N/A	N/A	1966
Dr. Gabrielle M. Siegers M.A., Ph.D.	Head of R&D	N/A	N/A	N/A
Dr. Srikanth Sola	Chief Strategy Officer	N/A	N/A	N/A
Dr. Christof Boehler	Chief Business Development Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Corporate Governance

Helix BioPharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.